On January 30, Takeda announced its performance report for the first three quarters of the 2024 fiscal year (April 2024 - March 2025). The total revenue was 3,528.2 billion yen (approximately $23.4 billion, calculated at the 2024 average exchange rate of 100 yen = 0.66323 USD), a 4.5% increase year-on-year (calculated at constant exchange rates). If calculated for the calendar year (January 2024 - December 2024), Takeda's total revenue for 2024 would reach 4,579.0 billion yen (approximately $30.37 billion).
In terms of regional distribution, the U.S. market contributed the highest revenue, reaching 2,351.7 billion yen (approximately $15.60 billion). Next were the combined European and Canadian markets with 1,040.9 billion yen (approximately $6.90 billion) and the Japanese market with 433.4 billion yen (approximately $2.87 billion).
Takeda divides its business into six major segments: Gastrointestinal (GI), Rare Diseases, Plasma Derived Therapies (PDT), Oncology, Vaccines, and Neurosciences.
The GI business accounts for the highest share of Takeda's overall revenue (29%), reaching 1,319.5 billion yen (approximately $8.75 billion). The core product of Takeda's GI business, the α4β7 monoclonal antibody Entyvio (Vedolizumab), has been on the market for more than ten years, with a 2024 revenue of 880.7 billion yen (approximately $5.84 billion). It is currently the best-selling biologic in the inflammatory bowel disease (IBD) field.
Looking ahead, the commercial outlook for Entyvio is not optimistic. On one hand, it will lose market exclusivity in the coming years as two biosimilars (PB016 and AVT16) have entered phase III clinical trials. On the other hand, it faces intense competition from other products in the same field, and new potential drugs targeting high-potential areas are already in late-stage development. Currently, IBD is no longer a niche market, with multinational pharmaceutical companies such as Merck and AbbVie entering this field through various transactions, attracting numerous companies to join.
To address Entyvio's patent cliff, Takeda made a significant acquisition in December 2022 by acquiring Nimbus Therapeutics' TYK2 inhibitor Zasocitinib (TAK-279). This drug not only has potential for treating IBD but also shows promise in autoimmune diseases like plaque psoriasis. Zasocitinib is currently undergoing several phase III clinical trials, and Takeda expects to file for market approval in FY2026. Additionally, Takeda expects to disclose phase IIb data for Zasocitinib in treating ulcerative colitis and Crohn's disease in FY2026.
In the rare disease field, Takeda is focused on breakthrough therapies for Hereditary Angioedema (HAE). Takhzyro (Lanadelumab), which has been on the market for over six years, is the only long-term prevention option for people aged 2 and above in the HAE field. In 2024, Takhzyro generated 210.2 billion yen (approximately $1.39 billion) in revenue for Takeda. However, it also faces significant competition, such as the gene-editing therapy NTLA-2002, which is in phase III clinical trials and may provide a functional cure for HAE.
Takeda's PDT business also contributes significantly to its overall revenue, with a total income of 1,013.3 billion yen (approximately $6.72 billion). Immunoglobulin (subcutaneous human immunoglobulin) contributed 735.0 billion yen (approximately $4.88 billion), making it Takeda's second-largest revenue product. In the future, Takeda plans to continue investing in the development of innovative and differentiated immunoglobulin products.
In the oncology field, Takeda achieved impressive commercialization results with Fruzaqla (Fuquatinib), introduced through a partnership with Huang Medical, generating 43.8 billion yen (approximately $290 million) in revenue for 2024, surpassing Takeda's original expectations. Fruzaqla is an innovative treatment option for colorectal cancer patients, providing significant survival benefits for metastatic colorectal cancer patients as a second-line treatment, regardless of biomarker status.
In the neuroscience field, Takeda is focusing on Attention Deficit Hyperactivity Disorder (ADHD). With Vyvanse/Elvanse (Lisdexamfetamine), Adderall XR (Amphetamine + Dextroamphetamine), and Intuniv (Guanfacine), Takeda has established a market position in this field. Vyvanse/Elvanse is also the only treatment option for binge eating disorder. However, this product lost market exclusivity in August 2023, and its sales are now on a decline.
In addition to advancing product development, Takeda is also looking for suitable targets to enrich its pipeline. In 2024, Takeda completed four significant transactions in the neuroscience and hematology fields, including a $2.2 billion partnership with AC Immune, acquiring global rights to Orebaxtinib (Orebanti) from Ascentage Pharma for $1.375 billion, an investment of $1.3 billion to introduce an innovative hematology drug, and a $1.2 billion investment in Dago Biotech to develop molecular glue degraders.
In addition to the financial report, Takeda also announced a personnel change. Current President, CEO, and Representative Director Christophe Weber will retire in June 2026, and Julie Kim, the current President of Takeda's U.S. Business Division, will succeed him.
